SWOG S1806 — Chemoradiation with or without atezolizumab for localized muscle-invasive bladder cancer

Phase 3 · Bladder Cancer

Population

Localized muscle-invasive bladder cancer undergoing bladder-preserving chemoradiation.

Primary Endpoint

Bladder-intact event-free survival

Rationale

Bladder-preserving chemoradiation avoids cystectomy, but relapse remains common. S1806 tests whether adding atezolizumab improves outcomes while keeping the bladder intact.

What It Could Change

Could add immunotherapy to bladder-preserving treatment as a stronger alternative to cystectomy.